Literature DB >> 26759237

RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway.

Fatéméh Dubois1, Maureen Keller1, Olivier Calvayrac2, Fabrice Soncin3, Lily Hoa4, Alexander Hergovich4, Maria-Carla Parrini5, Julien Mazières2, Mélissa Vaisse-Lesteven6, Jacques Camonis5, Guénaëlle Levallet7, Gérard Zalcman8.   

Abstract

Inactivation of the tumor suppressor gene RASSF1A by promoter hypermethylation represents a key event underlying the initiation and progression of lung cancer. RASSF1A inactivation is also associated with poor prognosis and may promote metastatic spread. In this study, we investigated how RASSF1A inactivation conferred invasive phenotypes to human bronchial cells. RNAi-mediated silencing of RASSF1A induced epithelial-to-mesenchymal transition (EMT), fomenting a motile and invasive cellular phenotype in vitro and increased metastatic prowess in vivo. Mechanistic investigations revealed that RASSF1A blocked tumor growth by stimulating cofilin/PP2A-mediated dephosphorylation of the guanine nucleotide exchange factor GEF-H1, thereby stimulating its ability to activate the antimetastatic small GTPase RhoB. Furthermore, RASSF1A reduced nuclear accumulation of the Hippo pathway transcriptional cofactor Yes-associated protein (YAP), which was reinforced by RhoB activation. Collectively, our results indicated that RASSF1 acts to restrict EMT and invasion by indirectly controlling YAP nuclear shuttling and activation through a RhoB-regulated cytoskeletal remodeling process, with potential implications to delay the progression of RASSF1-hypermethylated lung tumors. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26759237     DOI: 10.1158/0008-5472.CAN-15-1008

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  RASSF1A methylation, YAP1 activation and metastasis: a new role for an old foe in lung cancer.

Authors:  Min Hee Oh; William W Lockwood
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 2.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

3.  Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration.

Authors:  Brian J Pepe-Mooney; Michael T Dill; Anna Alemany; Jose Ordovas-Montanes; Yuki Matsushita; Anuradha Rao; Anushna Sen; Makoto Miyazaki; Sayeepriyadarshini Anakk; Paul A Dawson; Noriaki Ono; Alex K Shalek; Alexander van Oudenaarden; Fernando D Camargo
Journal:  Cell Stem Cell       Date:  2019-05-09       Impact factor: 24.633

Review 4.  The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Authors:  Xiao-Lan Liu; Rui Zuo; Wen-Bin Ou
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

5.  Dual-functionality of RASSF1A overexpression in A375 cells is mediated by activation of IL-6/STAT3 regulatory loop.

Authors:  Mei Yi; Wei Wang; Shengnan Chen; Ya Peng; Junjun Li; Jing Cai; Ying Zhou; Qian Peng; Yuanyuan Ban; Zhaoyang Zeng; Xiaoling Li; Wei Xiong; Guiyuan Li; Bo Xiang
Journal:  Mol Biol Rep       Date:  2018-08-03       Impact factor: 2.316

Review 6.  RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.

Authors:  Olivier Calvayrac; Anne Pradines; Gilles Favre
Journal:  Small GTPases       Date:  2016-11-01

Review 7.  Ras signaling through RASSF proteins.

Authors:  Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark
Journal:  Semin Cell Dev Biol       Date:  2016-06-08       Impact factor: 7.727

Review 8.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

Review 9.  The STK38-XPO1 axis, a new actor in physiology and cancer.

Authors:  Alexandre Pj Martin; Vasily N Aushev; Gérard Zalcman; Jacques H Camonis
Journal:  Cell Mol Life Sci       Date:  2020-11-03       Impact factor: 9.261

Review 10.  Lung cancer and epithelial-mesenchymal transition.

Authors:  Toshi Menju; Hiroshi Date
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.